M&A Deal Summary

Novo Holdings A/S Acquires Ellab

On June 21, 2023, corporate investor Novo Holdings A/S acquired medical products company Ellab from EQT

Acquisition Highlights
  • This is Novo Holdings A/S’s 2nd transaction in the Medical Products sector.
  • This is Novo Holdings A/S’s 3rd transaction in Denmark.

M&A Deal Summary

Date 2023-06-21
Target Ellab
Sector Medical Products
Buyer(s) Novo Holdings A/S
Sellers(s) EQT
Deal Type Secondary Buyout

Target

Ellab

Hilleroed, Denmark
website
Ellab is a manufacturer of solutions for measuring, recording, monitoring, and validating critical parameters of thermal processing. Ellab offers a product range of high-precision systems for temperature, pressure, and humidity monitoring and validation based on either data loggers or thermocouple-based wired instruments. Ellab was founded in 1949 and is based in Hilleroed, Denmark.

Search 192,510 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

DESCRIPTION

Novo Holdings A/S is a Danish holding company and the investment arm of the Novo Nordisk Foundation. Novo Holdings' objective is to grow the assets of the Foundation and improve the lives of people around the world. In addition to investing in equity and fixed income securities, Novo Holdings pursues direct investments in life science companies. Novo Holdings A/S was established in 1999 and is headquartered in Hellerup, Denmark.


DEAL STATS #
Overall 11 of 12
Sector (Medical Products) 2 of 2
Type (Secondary Buyout) 8 of 8
Country (Denmark) 3 of 3
Year (2023) 2 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2023-06-06 Paratek Pharmaceuticals

Boston, Massachusetts, United States

Paratek Pharmaceuticals is a bio-pharmaceutical company focused on the development and commercialization of innovative therapies based upon its expertise in novel tetracycline chemistry. Paratek Pharmaceuticals was founded in 1996 and is based in Boston, Massachusetts.

Buy $462M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2024-02-05 Catalent

Somerset, New Jersey, United States

Catalent is a provider of solutions for drugs, biologics and consumer health products. Among its core offerings, it develops and manufactures oral and sterile medication in nearly all dosage forms, holds patents for softgel (e.g. “Liqui-Caps” and “Vegicaps”) and Zydis fast-dissolve technologies used in many popular prescription and over-the-counter medicine. Catalent was founded in 2007 and is based in Somerset, New Jersey.

Buy $16.5B

Seller(S) 1

SELLER

EQT

Stockholm, Sweden

Investor Investor Investor Investor Investor

website


Category Private Equity Firm
Founded 1994
PE ASSETS 50.0B EUR
Size Mega
Type Sector Agnostic
DESCRIPTION

EQT is a global private equity group that purses a variety of investment strategies around the world. EQT is divided into several investment disciplines, including private capital, real assets, credit, and venture. The Firm's private capital group targets large, market-leading enterprises (investment size of €125 to €1.5 billion) across Europe and the US, as well as mid-market, growth companies (investment size of €40 to €125 million) across the US, Europe, China, and Southeast Asia. The Firm's real assets group seeks to identify control or co-control equity investments (investment size of €500 to €1 billion) in medium-sized infrastructure companies that provide an essential service to society, are recession resilient, and have secure cash flows. EQT's credit group provides flexible, long-term debt capital solutions to medium-sized European businesses, across a wide range of sectors. EQT was established in 1994 and is headquartered in Stockholm, Sweden.


DEAL STATS #
Overall 170 of 175
Sector (Medical Products) 10 of 12
Type (Secondary Buyout) 52 of 55
Country (Denmark) 20 of 20
Year (2023) 4 of 7
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2023-06-20 HDFC Credila

Mumbai, India

HDFC Credila is an education loan company, supporting tens of thousands of Indian students every year with tailored financing solutions for undergraduate and postgraduate studies. HDFC Credila is based in Mumbai, India.

Buy Rs10.0B
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2023-07-20 Dechra Pharmaceuticals

Northwich, United Kingdom

Dechra Pharmaceuticals is an international specialist in veterinary pharmaceuticals and related products business. Its expertise is in the development, manufacturing, sales, and marketing of quality products exclusively for veterinarians worldwide. The company's business is unique as the majority of its products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products. Dechra Pharmaceuticals was founded in 1998 and is based in Northwich, United Kingdom.

Buy £4.5B